2021 wholesale price Chemiluminescence (CLIA) - COVID-19 IgM/IgG Lateral Flow Assay – Genobio


Product Detail

Product Tags

Related Video

Feedback (2)

We try for excellence, service the customers", hopes to be the most effective cooperation workforce and dominator company for staff, suppliers and shoppers, realizes price share and ongoing marketing for oxacillinase-23, COVID-19 IgG antibody, aspergillus IgM, We have been in procedure for more than 10 years. We're dedicated to excellent solutions and consumer aid. We invite you to definitely pay a visit to our business for a personalized tour and advanced small business guidance.
2021 wholesale price Chemiluminescence (CLIA) - COVID-19 IgM/IgG Lateral Flow Assay – Genobio Detail:

Product Introduction

Virusee® COVID-19 IgM/IgG Lateral Flow Assay is a lateral flow immunoassay used for in vitro qualitative detection of novel coronavirus (SARS-CoV-2) IgM / IgG antibodies in human venipuncture whole blood, plasma, and serum specimens.

The novel coronavirus is a positive single-stranded RNA virus. Unlike any known coronavirus, the vulnerable population for Novel Coronavirus is generally susceptible, and it is more threatening to the elderly or people with fundamental diseases. IgM/IgG antibodies positive is an important indicator of novel coronavirus infections. Detection of novel coronavirus-specific antibodies will aid clinical diagnosis.

Characteristics

Name

COVID-19 IgM/IgG Lateral Flow Assay

Method

Lateral Flow Assay

Sample type

Blood, plasma, serum

Specification

20 tests/kit

Detection time

10 min

Detection objects

COVID-19

Stability

The kit is stable for 1 year at 2-30°C

COVID-19 IgMIgG Lateral Flow Assay

Advantage

  • Rapid
    Obtain result within 10 min
  • Simple
    Visually reading result, easy to interpret
    Simple procedure, without complicated operation
  • Cost-saving
    Product can be transported and stored at room temperature, reducing costs
  • Low risk
    Testing blood sample, reducing the risk of sampling process
  • Suitable for screening on-site, bedside, outpatient

Background and principle

The novel coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV)-2, has been identified as the causative pathogen of coronavirus disease 2019 (COVID-19). This disease has been called a public health emergency of international concern by the World Health Organization (WHO).

COVID-19 targets the upper and lower respiratory systems and causes flu-like symptoms in most infected people. Although many COVID-19 patients experience only mild symptoms, some patients have severe symptoms leading to massive lung damage. Treatment options for COVID-19 are limited and the crude mortality rate estimated by the WHO is around 2.9%. Although a preventive vaccine for COVID-19 could eventually become available, unless sufficient herd immunity is achieved, COVID-19 could potentially cause significant morbidity and mortality over the coming years.

After suffering from an infection, it is common to develop an antibody response against a particular pathogen. Early after infection (usually after the first week), a class of antibodies known as immunoglobulin M (IgM) develops, although these are not typically long-lasting. Later, after the first 2-4 weeks following infection, IgG, a more durable antibody, is produced.

Studies have found that RBD-targeted antibodies are excellent markers of previous and recent infection, that differential isotype measurements can help distinguish between recent and older infections. The detection of IgM and IgG antibodies against SARS-CoV-2 has potential significance for evaluating the severity and prognosis of COVID-19, and even increasing the detection accuracy of nuclear acid test.

The detection of SARS-CoV-2 IgM and IgG is very important to determine the course of COVID-19. Nucleic acid detection combined with serum antibody of SARS-CoV-2 may be the best laboratory indicator for the diagnosis of SARS-CoV-2 infection and the phrase and predication for prognosis of COVID-19.

COVID-19 IgG Lateral Flow Assay 1
COVID-19 IgG Lateral Flow Assay 2

Test process

COVID-19 IgMIgG Lateral Flow Assay 3

Order Information

Model

Description

Product code

VMGLFA-01

20 test/kit, cassette format

CoVMGLFA-01


Product detail pictures:

2021 wholesale price Chemiluminescence (CLIA) - COVID-19 IgM/IgG Lateral Flow Assay – Genobio detail pictures

2021 wholesale price Chemiluminescence (CLIA) - COVID-19 IgM/IgG Lateral Flow Assay – Genobio detail pictures

2021 wholesale price Chemiluminescence (CLIA) - COVID-19 IgM/IgG Lateral Flow Assay – Genobio detail pictures


Related Product Guide:

We can easily normally satisfy our respected buyers with our excellent high-quality, excellent selling price and good service due to we've been far more expert and more hard-working and do it in cost-effective way for 2021 wholesale price Chemiluminescence (CLIA) - COVID-19 IgM/IgG Lateral Flow Assay – Genobio , The product will supply to all over the world, such as: Nicaragua, Benin, Senegal, Our company follows laws and international practice. We promise to be responsible for friends, customers and all partners. We would like to establish a long-term relationship and friendship with every customer from all over the world on the basis of mutual benefits. We warmly welcome all old and new customers to visit our company to negotiate business.
  • This enterprise in the industry is strong and competitive, advancing with the times and develop sustainable, we are very pleased to have a opportunity to cooperate!
    5 Stars By Betsy from Tunisia - 2017.05.21 12:31
    The factory has advanced equipment, experienced staffs and good management level, so product quality had assurance, this cooperation is very relaxed and happy!
    5 Stars By Doris from Nepal - 2018.06.30 17:29
    Write your message here and send it to us